ImmunArray Expands MS IP Portfolio with Licensing Agreement
Wednesday, December 18, 2013
ImmunArray, developer of a groundbreaking in-vitro diagnostic platform system, the iCHIP™, has completed a licensing agreement with Brigham and Women’s Hospital, a teaching Hospital of Harvard Medical School, to advance their growing portfolio of MS capabilities; the intellectual property rights relate to unique cholesterol derivatives and antigen arrays in the diagnosis of Progressive Multiple Sclerosis. In addition, the company has received additional investments by Virginia Life Sciences Investments Affiliates to support its ongoing development of additional products and plan for market entry.
"ImmunArray has developed a proprietary diagnostic technology that has the capability of revolutionizing the personal medicine industry,” said Donna J. Edmonds VLSI CEO and Chairman of ImmunArray. "We view Immunarray as a key technology platform in our portfolio of maturing companies; its approach to use the immune system as a source of critical and evolving information has proven to be increasingly important as we work with pharmaceutical companies in drug development and the early detection of critical shifts in the state of the body. ImmunArray’s cost-effective early diagnostic and therapy monitoring technology profiles the antibody repertoire in blood, saliva or other body fluids. These profiles can be used for a broad series of applications. The Company holds an exclusive, worldwide license from the Weizmann Institute of Science to develop and commercialize the ImmunArray iCHIP™ technology. It also has an expanding intellectual property portfolio around disease specific applications including Type 1 Diabetes, SLE and MS."
The company also recently presented additional data on their product(s) being developed to support the diagnosis, monitoring and rule out of Systemic Lupus Erythematosus (SLE) at the at the American College of Rheumatology (ACR) in San Diego, the third presentation at a major scientific and clinical meeting this year. These data were developed in conjunction with academic centers in both the US and Israel. Transplant continues to be an additional market the company is evaluating in conjunction with a major pharmaceutical company with products in this market. All products will be supported and available through Veracis™, the company’s service laboratory located on the campus of the Johns Hopkins Bayview Medical Center in Baltimore Maryland."
Scott Batty, ImmunArray, Ltd. CEO added. "The recent data surrounding our test for SLE was very well received at the American College of Rheumatology, and was also presented at this year’s American Association of Immunology in Honolulu as well as the International Congress of Immunologists in Milan in August. A manuscript, "EBV Antibodies Mark SLE and Scleroderma Patients Negative for Anti-DNA; Fattal I, et al” has been accepted for publication in Immunology, a key journal, and will be available shortly for the clinical community. These presentations to the premier annual meetings of medical and scientific community in Immunology highlights a peer review acceptance of the novelty and interest in this technology for solving real clinical problems. We are also encouraged by the growing extensive interest from the pharmaceutical community in assessing where our technology can meet their needs and improve their development efficiency and likelihood of commercial success in selected products. We are grateful for the continued endorsement by our investors validating the multiple channels for commercial success and demonstrates continued support in our ability to execute on the programs currently underway.”